Xenon Pharmaceuticals Inc. (XENE)
Nasdaq: XENE · Pharmaceutical Preparations · filing with the SEC since 2013
Who owns Xenon Pharmaceuticals Inc.
As filed with the SECHolders of 5% or more
3
Fmr LLC holds 10.3% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 7, 2026 says.
Directors and officers
12
report now, of 27 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 7, 2026 · COMMON STOCK · 9.9% in Aug 6, 2026
Avoro Capital Advisors LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Shares, no par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Jul 17, 2025 · Common Stock
Driehaus Capital Management LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · reported falling below 5%
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Shares · reported falling below 5%, from 5.1% in Nov 14, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · reported falling below 5%, from 6.2% in Feb 10, 2026
What XENE reports owning in othersstakes of 5% or more, and other ties
Xenon Pharmaceuticals Inc. reports no stake in another company in the record.
Insider tradesForm 4
26sales
2purchases
25sales on a scheduled plan
6people selling
$22.0Msold, in dollars
$1.7Mbought, in dollars
Open-market trades on Form 4 from Oct 16, 2025 to Oct 16, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 16, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mortimer Ian | PRESIDENT & CEO | 17 | $20.3M | 17 | 1 | $1.1M |
| Kenney Christopher John | Chief Medical Officer | 4 | $700,000 | 4 | 0 | $0 |
| Gannon Steven | director | 1 | $600,000 | 0 | 0 | $0 |
| Difabio Andrea | Chief Legal Officer | 2 | $200,000 | 2 | 0 | $0 |
| Cannon Gillian | director | 1 | $100,000 | 1 | 0 | $0 |
| Patou Gary | director | 1 | $100,000 | 1 | 0 | $0 |
| Kelly Thomas Patrick | Chief Financial Officer | 0 | $0 | 0 | 1 | $600,000 |